Article Details
Retrieved on: 2024-10-26 17:17:13
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Following the successful market launch of a subretinal gene augmentation therapy for IRDs caused by biallelic RPE65 mutations (voretigene neparvovec, ...
Article found on: www.nature.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here